RE:Here is a quote from Heineman (ONC/Y Chief Medical Officer)
What I particularly like about this treatment as that it is being used in first line patients if I recall correctly. With this being the case, the patients usually still have a stronger immune system which then also allows for a stronger response to the treatiment IMO....This being said, onc could or should possibly become a first line treatment in a lot of cancer indications rather than being a 2nd or 3rd or last resort which then sets the company up to become a new standard of care down the road and at the same time giving more hope for those who are receiving the drug in a 2nd or 3rd line treatment setting.